Circovirus sequences associated with piglet weight loss disease (PWD)
View Patent ↗The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1. A vaccine comprising an isolated nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID No. 23 and SEQ ID No. 25.
2. A vaccine according to claim 1 , wherein said nucleotide sequence is SEQ ID No. 15.
3. A vaccine according to claim 1 , further comprising an adjuvant.
4. A vaccine according to claim 1 , wherein said nucleic acid has a nucleotide sequence with at least 95% sequence identity to SEQ ID No. 15.
5. A vaccine of claim 4 , further comprising an adjuvant.
6. A vaccine according to claim 5 , wherein said nucleotide sequence is SEQ ID No. 15.
7. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of a vaccine, wherein said vaccine comprises an isolated nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to at least one of SEO ID No. 23 and SEQ ID No. 25.
8. A method according to claim 7 , wherein said nucleotide sequence is SEQ ID No. 15.
9. A method according to claim 7 , wherein said vaccine further comprises an adjuvant.
10. A method according to claim 7 , wherein said nucleic acid has a nucleotide sequence with at least 95% sequence identity to SEQ ID No. 15.
11. A method according to claim 10 , wherein said vaccine further comprises an adjuvant.
12. A method according to claim 11 , wherein said nucleotide sequence is SEQ ID No. 15.
13. A vaccine comprising, in an acceptable pharmaceutical vehicle, a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID No. 23 and SEQ ID No. 25.
14. A vaccine according to claim 13 , wherein said nucleotide sequence has at least 95% sequence identity to SEQ ID No. 15.
15. A vaccine according to claim 13 , wherein said nucleotide sequence consists essentially of SEQ ID No. 15.
16. A vaccine according to claim 13 , wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 23.
17. A vaccine according to claim 13 , wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 23.
18. A vaccine according to claim 17 , wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.
19. A vaccine according to claim 17 , wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.
20. A vaccine according to claim 16 , wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.
21. A vaccine according to claim 16 , wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.
22. A vaccine according to claim 13 , wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.
23. A vaccine according to claim 13 , wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.
24. A vaccine according to claim 13 , wherein said nucleotide sequence consists of SEQ ID No. 15.
25. A vaccine comprising, in an acceptable pharmaceutical vehicle, a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to at least one of SEQ ID No. 23 and SEQ ID No. 25.
26. A vaccine according to claim 25 , wherein said nucleotide sequence has at least 95% sequence identity to SEQ ID No. 15.
27. A vaccine according to claim 25 , wherein said nucleotide sequence consists essentially of SEQ ID No. 15.
28. A vaccine according to claim 25 , wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 23.
29. A vaccine according to claim 25 , wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 23.
30. A vaccine according to claim 29 , wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.
31. A vaccine according to claim 29 , wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.
32. A vaccine according to claim 28 , wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.
33. A vaccine according to claim 28 , wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.
34. A vaccine according to claim 25 , wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.
35. A vaccine according to claim 25 , wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.
36. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of a vaccine, wherein said vaccine comprises, in an acceptable pharmaceutical vehicle, a nucleic acid having a nucleotide sequence with at least 95% sequence identity to SEQ ID No. 15, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to at least one of SEQ ID No. 23 and SEQ ID No. 25.
37. A method according to claim 36 , wherein said nucleotide sequence consists essentially of SEQ ID No. 15.
38. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of a vaccine, wherein said vaccine comprises, in an acceptable pharmaceutical vehicle, a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 15, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus, wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to at least one of SEQ ID No. 23 or SEQ ID No. 25.
39. A method according to claim 38 , wherein said nucleotide sequence has at least 95% sequence identity to SEQ ID No. 15.
40. A method according to claim 38 , wherein said nucleotide sequence consists essentially of SEQ ID No. 15.
41. A method according to claim 38 , wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 23.
42. A method according to claim 38 , wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 23.
43. A method according to claim 42 , wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.
44. A method according to claim 42 , wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.
45. A method according to claim 41 , wherein said nucleotide sequence further comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.
46. A method according to claim 41 , wherein said nucleotide sequence further comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.
47. A method according to claim 38 , wherein said nucleotide sequence comprises a sequence having at least 90% sequence identity to SEQ ID No. 25.
48. A method according to claim 38 , wherein said nucleotide sequence comprises a sequence having at least 95% sequence identity to SEQ ID No. 25.
49. A method according to claim 38 , wherein said nucleotide sequence consists of SEQ ID No. 15.